Gilead Sciences, Inc. (GILD)
Largest Insider Buys in Sector
GILD Stock Price History Chart
GILD Stock Performance
About Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, …
Insider Activity of Gilead Sciences, Inc.
Over the last 12 months, insiders at Gilead Sciences, Inc. have bought $0 and sold $7.73M worth of Gilead Sciences, Inc. stock.
On average, over the past 5 years, insiders at Gilead Sciences, Inc. have bought $0 and sold $6.02M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $2M was made by WOLD OLSEN PER (director) on 2015‑02‑06.
List of Insider Buy and Sell Transactions, Gilead Sciences, Inc.
| 2024-10-01 | Sale | Chief Medical Officer | 2,000 0.0002% | $83.83 | $167,660 | +2.62% | ||
| 2024-09-12 | Sale | Chief Medical Officer | 21,246 0.0017% | $84.50 | $1.8M | +2.85% | ||
| 2024-09-12 | Sale | Chief Commercial Officer | 29,357 0.0024% | $83.78 | $2.46M | +2.85% | ||
| 2024-08-28 | Sale | Chief Commercial Officer | 9,513 0.0008% | $78.03 | $742,299 | +7.03% | ||
| 2024-08-13 | Sale | Chief Commercial Officer | 5,490 0.0004% | $73.98 | $406,150 | 0.00% | ||
| 2024-07-01 | Sale | Chief Medical Officer | 2,000 0.0002% | $68.63 | $137,260 | 0.00% | ||
| 2024-04-01 | Sale | Chief Medical Officer | 2,000 0.0002% | $72.96 | $145,920 | -0.86% | ||
| 2024-02-29 | Sale | Chief Medical Officer | 8,230 0.0007% | $72.74 | $598,624 | +1.26% | ||
| 2024-02-28 | Sale | Chief Medical Officer | 2,000 0.0002% | $73.18 | $146,360 | +0.40% | ||
| 2024-01-16 | Sale | Chief Financial Officer | 5,000 0.0004% | $85.78 | $428,900 | -14.50% | ||
| 2024-01-09 | Sale | Chief Commercial Officer | 8,242 0.0007% | $85.23 | $702,466 | -14.56% | ||
| 2023-10-17 | Sale | Chief Financial Officer | 5,000 0.0004% | $80.00 | $400,017 | -6.68% | ||
| 2023-09-12 | Sale | Chief Medical Officer | 1,501 0.0001% | $76.99 | $115,562 | -2.57% | ||
| 2023-07-20 | Sale | Chief Financial Officer | 5,000 0.0004% | $80.00 | $400,000 | -5.94% | ||
| 2023-06-13 | Sale | Chief Medical Officer | 1,485 0.0001% | $76.90 | $114,197 | -2.34% | ||
| 2023-03-13 | Sale | Chief Medical Officer | 6,126 0.0005% | $78.99 | $483,893 | -0.46% | ||
| 2023-03-01 | Sale | Chief Medical Officer | 12,984 0.001% | $79.96 | $1.04M | -0.40% | ||
| 2022-12-30 | Sale | Chief Medical Officer | 553 <0.0001% | $85.33 | $47,187 | -7.23% | ||
| 2022-11-09 | Sale | SVP, Controller & CAO | 6,416 0.0005% | $83.50 | $535,736 | -1.53% | ||
| 2022-11-01 | Sale | SVP, Controller & CAO | 16,255 0.0013% | $79.25 | $1.29M | +2.12% |
Insider Historical Profitability
| MARTIN JOHN C | director | 2877762 0.2311% | $91.49 | 1 | 157 | +15.06% |
| MILLIGAN JOHN F | President and CEO | 1165924 0.0936% | $91.49 | 1 | 53 | +12.4% |
| WOLD OLSEN PER | director | 97854 0.0079% | $91.49 | 4 | 3 | +18.87% |
| HILLS CARLA A | director | 2742 0.0002% | $91.49 | 2 | 0 | <0.0001% |
Institutional Investor Ownership
| BlackRock | $8.98B | 9.84 | 122.53M | -0.21% | -$19.19M | 0.2 | |
| The Vanguard Group | $8.4B | 9.21 | 114.73M | +2.6% | +$213.17M | 0.16 | |
| Capital World Investors | $6.19B | 6.78 | 84.5M | +1.36% | +$83.01M | 1.03 | |
| Capital Research Global Investors | $4.49B | 4.92 | 61.25M | +2.66% | +$116.41M | 1.02 | |
| State Street | $4.23B | 4.63 | 57.7M | -3.08% | -$134.16M | 0.17 |